Amneal (NYSE: AMRX) Co-CEO settles RSUs, withholds stock to cover taxes

Filing Impact

(Very High)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Amneal Pharmaceuticals, Inc. director and Co-CEO Chintu Patel reported vesting and settlement of several equity awards into Class A Common Stock. On March 3, 2026, performance-based restricted stock units granted on March 3, 2023 were certified at 200% of the targeted number, deemed earned and vested, and settled into shares on a one-for-one basis. Time-based restricted stock units also vested and were settled into Class A shares.

The gross shares issued from these vestings were partly withheld to cover tax withholding obligations, with multiple Form 4 code “F” transactions showing Class A shares withheld at $13.31 and $13.30 per share for taxes. After these transactions, Patel directly holds 1,388,521 shares of Class A Common Stock and 185,185 restricted stock units, and indirectly holds 24,753,252 Class A shares through family trusts.

Insider Trade Summary

886,468 shares exercised/converted

Mixed 10 txns

Insider Patel Chintu

Role Co-CEO

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	92,593	$0.00	--
Exercise	Class A Common Stock	92,593	$0.00	--
Tax Withholding	Class A Common Stock	28,983	$13.30	$385K
Exercise	Restricted Stock Units	59,931	$0.00	--
Exercise	Performance-Based Restricted Stock Units	733,944	$0.00	--
Exercise	Class A Common Stock	59,931	$0.00	--
Tax Withholding	Class A Common Stock	17,112	$13.31	$228K
Exercise	Class A Common Stock	733,944	$0.00	--
Tax Withholding	Class A Common Stock	315,885	$13.31	$4.20M
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Restricted Stock Units — 185,185 shares (Direct); Class A Common Stock — 1,417,504 shares (Direct); Performance-Based Restricted Stock Units — 0 shares (Direct); Class A Common Stock — 24,753,252 shares (Indirect, By Family Trusts)

Footnotes (1)

Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5. Represents shares of common stock withheld to satisfy tax withholding obligations relating to vesting of performance-based restricted stock units. On March 3, 2025, the Reporting Person was granted 239,726 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. On March 4, 2024, the reporting person was granted 370,370 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

Form 4 Insider Transactions: What Each Field Means →

03/05/2026 - 04:52 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Chintu

(Last)

(First)

(Middle)

C/O AMNEAL PHARMACEUTICALS, INC.

400 CROSSING BOULEVARD

(Street)

BRIDGEWATER

08807

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Amneal Pharmaceuticals, Inc. [ AMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Co-CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	03/03/2026		M		59,931⁽¹⁾	A	⁽²⁾	923,964	D
Class A Common Stock	03/03/2026		F		17,112⁽³⁾	D	$13.31	906,852	D
Class A Common Stock	03/03/2026		M		733,944	A	⁽⁴⁾	1,640,796	D
Class A Common Stock	03/03/2026		F		315,885⁽⁵⁾	D	$13.31	1,324,911	D
Class A Common Stock	03/04/2026		M		92,593⁽¹⁾	A	⁽²⁾	1,417,504	D
Class A Common Stock	03/04/2026		F		28,983⁽³⁾	D	$13.3	1,388,521	D
Class A Common Stock								24,753,252	I	By Family Trusts

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽²⁾	03/03/2026		M			59,931	⁽⁶⁾	⁽⁶⁾	Class A Common Stock	59,931	$0	179,795	D
Performance-Based Restricted Stock Units	⁽⁴⁾	03/03/2026		M			733,944	⁽⁴⁾	⁽⁴⁾	Class A Common Stock	733,944	$0	0	D
Restricted Stock Units	⁽²⁾	03/04/2026		M			92,593	⁽⁷⁾	⁽⁷⁾	Class A Common Stock	92,593	$0	185,185	D

Explanation of Responses:

1. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.

2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

3. Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.

4. Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5.

5. Represents shares of common stock withheld to satisfy tax withholding obligations relating to vesting of performance-based restricted stock units.

6. On March 3, 2025, the Reporting Person was granted 239,726 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

7. On March 4, 2024, the reporting person was granted 370,370 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

Remarks:

	/s/ Denis Butkovic, Attorney-in-Fact	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Amneal Pharmaceuticals (AMRX) Co-CEO Chintu Patel report?

Chintu Patel reported vesting and settlement of restricted stock units and performance-based restricted stock units into Class A Common Stock. Some of the resulting shares were withheld at specified prices to satisfy tax withholding obligations related to these equity award vestings.

How many Amneal Pharmaceuticals (AMRX) shares does Chintu Patel hold after this Form 4?

After the reported transactions, Chintu Patel directly holds 1,388,521 shares of Amneal Class A Common Stock and 185,185 restricted stock units. He also indirectly holds 24,753,252 Class A shares through family trusts, as disclosed in the holding entry.

What happened to Amneal (AMRX) performance-based restricted stock units in this filing?

Performance-based restricted stock units granted on March 3, 2023 were certified as meeting a performance threshold that resulted in 200% of the targeted units vesting. These units were deemed earned and vested on March 3, 2026 and settled into Class A shares one-for-one.

Why were some Amneal (AMRX) shares disposed of in Chintu Patel’s Form 4?

Class A Common Stock shown with code “F” represents shares withheld to satisfy tax withholding obligations from vesting restricted stock units and performance-based restricted stock units. These are tax-withholding dispositions rather than open‑market sales by the Co‑CEO.

At what prices were Amneal (AMRX) shares withheld for taxes in this Form 4?

Shares withheld to cover tax obligations were recorded at prices of $13.31 and $13.30 per share. These prices apply to specific Form 4 code “F” transactions where Amneal Class A Common Stock was delivered to satisfy tax withholding on equity award vestings.

What future restricted stock unit vesting schedules are disclosed for Amneal (AMRX) Co-CEO Chintu Patel?

The filing notes 239,726 restricted stock units granted on March 3, 2025 and 370,370 restricted stock units granted on March 4, 2024. Each grant is scheduled to vest in four equal installments beginning on the first anniversary of its respective grant date.